Zomig-ZMT
Zomig-ZMT Brand names, Zomig-ZMT Analogs
Zomig-ZMT Brand Names Mixture
- No information avaliable
Zomig-ZMT Chemical_Formula
C16H21N3O2
Zomig-ZMT RX_link
http://www.rxlist.com/cgi/generic2/zolmit.htm
Zomig-ZMT fda sheet
Zomig-ZMT msds (material safety sheet)
Zomig-ZMT Synthesis Reference
No information avaliable
Zomig-ZMT Molecular Weight
287.357 g/mol
Zomig-ZMT Melting Point
No information avaliable
Zomig-ZMT H2O Solubility
No information avaliable
Zomig-ZMT State
Solid
Zomig-ZMT LogP
1.363
Zomig-ZMT Dosage Forms
Spray; Tablet
Zomig-ZMT Indication
For the acute treatment of adult migraine (with or without auras)
Zomig-ZMT Pharmacology
Zolmitriptan is a selective 5-hydroxytryptamine receptor subtype agonist indicated for the acute treatment of migraine attacks with or without aura in adults. Zolmitriptan is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine. Zolmitriptan is an agonist for a vascular 5-hydroxytryptamine receptor subtype (probably a member of the 5-HT1D family) having only a weak affinity for 5-HT1A, 5-HT5A, and 5-HT7 receptors and no significant affinity or pharmacological activity at 5-HT2, 5-HT3 or 5-HT4 receptor subtypes or at alpha1-, alpha2-, or beta-adrenergic, dopamine1,; dopamine2; muscarinic, or benzodiazepine receptors. This action in humans correlates with the relief of migraine headache. In addition to causing vasoconstriction, experimental data from animal studies show that Zolmitriptan also activates 5-HT1 receptors on peripheral terminals of the trigeminal nerve innervating cranial blood vessels, which may also contribute to the antimigrainous effect of Zolmitriptan in humans.
Zomig-ZMT Absorption
40%
Zomig-ZMT side effects and Toxicity
No information avaliable
Zomig-ZMT Patient Information
No information avaliable
Zomig-ZMT Organisms Affected
Humans and other mammals
